Gene Tools

{{short description|Biotechnology company}}

{{Infobox company

| name = Gene Tools, LLC

| logo = File:BlackLogoSmall.gif

| type =

| industry =

| fate =

| predecessor =

| successor =

| founded =

| founder =

| defunct =

| hq_location_city = Philomath, Oregon

| hq_location_country =

| area_served =

| key_people =

| products =

| owner =

| num_employees =

| num_employees_year =

| parent =

| website = {{URL|http://www.gene-tools.com/}}

}}

Gene Tools, LLC is a limited liability company located in Philomath, Oregon, United States that manufactures Morpholino antisense oligos and delivery reagents.{{cite journal | last = Summerton | first = JE | year = 2005 | title = Endo-porter: a novel reagent for safe, effective delivery of substances into cells. | journal = Ann N Y Acad Sci | volume = 1058 | issue = 1 | pages = 62–75 | doi = 10.1196/annals.1359.012 | pmid = 16394126 | bibcode = 2005NYASA1058...62S | s2cid = 28590429 }}{{cite journal | last = Morcos | first = PA | year = 2001 | title = Achieving efficient delivery of morpholino oligos in cultured cells. | journal = Genesis | volume = 30 | pages = 94–102 | pmid=11477682 | doi = 10.1002/gene.1039 | issue = 3 | doi-access = }} Gene Tools was founded in 1997 and began regularly shipping custom-sequence Morpholino oligos in 2000. Current products include Morpholino oligos and Vivo-Morpholinos (for improved delivery into cells).

The manager and general partner, Jim Summerton, is a pioneer in antisense research,{{cite journal | last = Summerton | first = JE | date= May 1979 | title = Intracellular inactivation of specific nucleotide sequences: a general approach to the treatment of viral diseases and virally-mediated cancers. | volume = 78 | pages = 77–99 | doi = 10.1016/0022-5193(79)90327-8 |journal=J. Theor. Biol. |issue=1 |pmid=114718 | bibcode = 1979JThBi..78...77S }} conceived of and was co-inventor of the Morpholino antisense oligo structural type{{cite journal | last = Summerton | first = J |author2=Weller D | year = 1997 | title = Morpholino Antisense Oligomers: Design, Preparation and Properties. | journal = Antisense & Nucleic Acid Drug Development | volume = 7 | pages = 187–95 |pmid=9212909 | issue = 3 | doi = 10.1089/oli.1.1997.7.187 | s2cid = 19372403 | url = http://pdfs.semanticscholar.org/200b/07f6f73a1b33b0cb11825655aeda076e935e.pdf | archive-url = https://web.archive.org/web/20190219225617/http://pdfs.semanticscholar.org/200b/07f6f73a1b33b0cb11825655aeda076e935e.pdf | url-status = dead | archive-date = 2019-02-19 }} and founded the first antisense therapeutics company, Sarepta Therapeutics Inc. (formerly AntiVirals Inc., renamed AVI BioPharma Inc., renamed Sarepta Therapeutics Inc.).